No actually it hasn't - I specifically asked a question in a presentation once about why they sought the patent if they never intended to tackle it and he was clear that while its not on the radar at the moment, you never know what the future holds and its good to have the protection.
I thought the answer was a little vague but suspect that the cards were close to the chest and think you need to read between the lines mate.
Autism is too big to tackle outright. Isolated conditions that are generally understood to fall within the ASD are a different story and if you can nail those, you can sell the big dream.
I could be TOTALLY wrong but was of the understanding that FX and Retts were on different ends of the spectrum - one was hyperactive neuronal connections and the other was hypoactive - and I thought it we could prove it works on both ends, we could tackle everything in between.
Not sure how I reached the conclusion but feel like I read it once.
NEU Price at posting:
$14.02 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)